EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving ...
PHILADELPHIA.Today on MSN
Breaking barriers: Empowering and understanding students with ADHD
Millions of students around the world are suffering every day, and many do not understand why their minds work differently ...
Last month, Southern Weekly reported on a policy at some hospitals in Shanxi requiring that ADHD patients get a "Class 1 ...
Annual prescriptions for drugs to treat attention-deficit/hyperactivity disorder (ADHD) increased 157 percent in Ontario from 2015 to 2023, according to a new study from researchers at ICES, North ...
Mental Health and Pain Medication Prescriptions for Young People Have Declined in the Past 20 Years The number of controlled ...
There are many myths about what ADHD is and is not due to misinformation and misunderstanding about the diagnosis.
A new Ontario-based study has found a significant rise in prescriptions for stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD), particularly among adults and females.
Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of ...
Medical Device Network on MSN
FDA greenlights Lumos Labs’ digital ADHD therapeutic
Lumos Labs’ LumosityRx is positioned for use alongside other ADHD treatment modalities such as medication and therapy.
Annual prescriptions for drugs to treat ADHD increased 157 percent in Ontario from 2015 to 2023, with greater increases among younger women compared to younger men.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback